IsoRay (ISR) Reports Q3 Loss of $0.02/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
IsoRay (ISR) Announces Publication of Positive Cesium-131 Data as Lung Cancer Treatment
May 20, 2015 8:19 AM EDTIsoRay (NYSE: ISR) announced the on-line publication of the first major peer reviewed study showing improved results using IsoRay's Cesium-131 seeds in the treatment of lung cancer.
IsoRay CEO Dwight Babcock commented, "We are extremely excited to have our Cesium-131 isotope seeds and mesh used in the treatment of non-small cell lung cancers with such outstanding patient outcomes. Notable physicians, including the authors of this study, are seeking... More
Maxim Still Bullish on IsoRay (ISR) Following Q1 Results; More Physicians Adopting Cesium-131
May 18, 2015 2:51 PM EDTMaxim Group affirms IsoRay (NYSE: ISR) with a Buy rating and $5 price target after the company reported reported Q3 EPS of ($0.02) with revenue of $1.16, versus EPS of ($0.05) and revenue of $1.13 million reported in the same period last year.
Analyst Jason Kolbert noted,... More
